Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Regeneron Pharmaceuticals, Inc. (REGN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions ...

Find the latest Regeneron Pharmaceuticals, Inc. (REGN) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Time now for to watch Friday, June 13th, starting off on the consumer monthly consumer sentiment data for June. It's coming out in the morning. Economist forecasting that number to rise compared ...